BMC Gastroenterology (Oct 2010)

Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome

  • Kapsoritaki Anastasia,
  • Valotassiou Varvara,
  • Tzavara Chara,
  • Georgoulias Panagiotis,
  • Kapsoritakis Andreas N,
  • Manolakis Anastassios C,
  • Potamianos Spyros P

DOI
https://doi.org/10.1186/1471-230X-10-118
Journal volume & issue
Vol. 10, no. 1
p. 118

Abstract

Read online

Abstract Background S100A12, a calcium-binding proinflammatory protein secreted by granulocytes, has been associated with different diseases of inflammatory origin, including inflammatory bowel disease (IBD). In this study, the utility of serum S100A12, in discriminating IBD from irritable bowel syndrome (IBS), was tested. Methods S100A12 serum levels were determined in 64 patients with ulcerative colitis (UC), 64 with Crohn's disease (CD) and 73 with IBS, by means of an enzyme-linked immunosorbent assay. S100A12 serum levels were evaluated with respect to the levels of known inflammatory markers and patients' characteristics. Results The median values of serum S100A12 levels were 68.2 ng/mL (range: 43.4-147.4) in UC, 70 ng/mL (41.4-169.8) in CD and 43.4 ng/mL (34.4-74.4) in IBS patients. UC and CD patients had significantly higher serum S100A12 levels compared to IBS patients (P = 0.001 for both comparisons). Moreover, a cut-off for serum S100A12 levels of 54.4 ng/mL could predict both UC and CD with a 66.7% sensitivity and a 64.4% specificity. The area under curve was estimated at 0.67 with a 95% confidence interval of 0.60-0.75 (P P = 0.001 and r = 0.23, P = 0.02 respectively). Conclusions Increased levels of circulating S100A12 are found in IBD, compared to IBS. When used to distinguish IBD from IBS adult patients, serum S100A12 levels exhibit moderate performance. On the other hand, serum S100A12 may serve as an inflammatory marker in IBD, since it is well correlated with CRP and SAA.